rethinkTHC Search
Menu
Study breakdown

Low-Dose Oral Cannabis Reversed Insulin Resistance in Diabetic Rats Through Different Mechanisms at Different Fat Sites

Animal StudyPreliminary evidence
The takeaway

A specific low dose of oral cannabis (1.25 mg/kg THC equivalent) reversed insulin resistance in obese diabetic rats, but the mechanism differed between peritoneal fat (activated fat "beigeing" genes) and intramuscular fat (increased mitochondrial activity).

Metabolic researchers, endocrinologists, scientists studying cannabis and obesity.

Only the lowest cannabis dose (1.25 mg/kg THC) reversed insulin resistance

What the researchers found

Cannabis at 1.25 mg/kg body weight (relative to THC content) reversed insulin resistance, while higher doses did not. In peritoneal fat, Cidea and UCP1 gene expression (fat beigeing markers) significantly increased. In intramuscular fat, mitochondrial activity increased significantly instead, without beigeing markers.

Why it matters

The dose-dependent reversal of insulin resistance, where only the lowest dose worked, challenges assumptions that more is better. The finding that different fat depots respond through different mechanisms adds complexity to understanding how cannabis affects metabolism.

The numbers in context

Effective dose: 1.25 mg/kg body weight (THC equivalent). Higher doses ineffective. Cidea and UCP1 significantly increased in peritoneal fat. Mitochondrial activity significantly increased in intramuscular fat.

How the study worked

Obese streptozotocin-induced diabetic rat model with oral cannabis administration at multiple doses, comparing effects at peritoneal and intramuscular fat depots.

What this study cannot tell us

Animal model using streptozotocin-induced diabetes, which differs from naturally occurring type 2 diabetes. Only tested oral cannabis, not isolated cannabinoids. Small sample typical of animal studies. Cannot directly extrapolate doses to humans.

How to read the evidence

Animal study using a streptozotocin-induced diabetes model. Results are preliminary and require human validation.

When this study was published

Published in 2023.

The bigger picture

Epidemiological studies have repeatedly found that cannabis users have lower rates of obesity and diabetes despite increased caloric intake. This animal study offers a possible mechanism, though the narrow effective dose range raises questions about translating these findings to humans.

Questions still open

  • Why did only the lowest dose reverse insulin resistance?
  • Could this dose-response pattern explain contradictory findings in human metabolic studies?

Common questions

Can cannabis treat diabetes?
In this rat study, a specific low dose of oral cannabis reversed insulin resistance, but higher doses did not. This is preclinical evidence and has not been confirmed in humans.
How did cannabis affect fat in this study?
It activated fat "beigeing" genes in belly fat and increased mitochondrial activity in muscle fat, suggesting different mechanisms at different fat sites.

Read the original research

Effect of oral cannabis administration on the fat depots of obese and streptozotocin-induced diabetic rats.

Phytotherapy research : PTR, 37(5), 1806-1822

Citation

Ramlugon, Sonaal; Levendal, Ruby-Ann; Frost, Carminita L. (2023). Effect of oral cannabis administration on the fat depots of obese and streptozotocin-induced diabetic rats.. Phytotherapy research : PTR, 37(5), 1806-1822. https://doi.org/10.1002/ptr.7694

Explore the wider topic